Stock Research: Esperion Therapeutics

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Esperion Therapeutics

NasdaqGM:ESPR US29664W1053
42
  • Value
    15
  • Growth
    79
  • Safety
    Safety
    79
  • Combined
    67
  • Sentiment
    18
  • 360° View
    360° View
    42
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Esperion Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing oral, non-statin medicines for cardiovascular disease. Its products include NEXLETOL, NEXLIZET, NILEMDO, and NUSTENDI, aimed at lowering elevated LDL-C and cardiovascular risk. In the last fiscal year, the company had 304 employees, a market cap of $228 million, profits of $264 million, and revenue of $332 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 42 (better than 42% compared with alternatives), overall professional sentiment and financial characteristics for the stock Esperion Therapeutics are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Esperion Therapeutics. The consolidated Value Rank has an attractive rank of 79, which means that the share price of Esperion Therapeutics is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 79% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 79, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 18. Professional investors are more confident in 82% other stocks. Worryingly, the company has risky financing, with a Safety rank of 15. This means 85% of comparable companies have a safer financing structure than Esperion Therapeutics. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
79 80 88 55
Growth
79 77 33 7
Safety
Safety
15 37 28 8
Sentiment
18 10 45 1
360° View
360° View
42 47 39 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
15 36 57 9
Opinions Change
87 31 50 37
Pro Holdings
n/a 28 32 53
Market Pulse
31 11 48 20
Sentiment
18 10 45 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
79 80 88 55
Growth
79 77 33 7
Safety Safety
15 37 28 8
Combined
67 84 49 4
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
7 7 100 14
Price vs. Earnings (P/E)
66 76 82 38
Price vs. Book (P/B)
92 92 100 92
Dividend Yield
1 1 1 1
Value
79 80 88 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
6 43 98 17
Profit Growth
86 86 51 12
Capital Growth
83 98 1 95
Stock Returns
83 29 11 5
Growth
79 77 33 7
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
8 25 14 1
Refinancing
37 74 73 69
Liquidity
48 24 31 23
Safety Safety
15 37 28 8

Similar Stocks

Discover high‑ranked alternatives to Esperion Therapeutics and broaden your portfolio horizons.

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Intuit

NasdaqGS:INTU
Country: USA
Industry: Application Software
Size: X-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.